gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Platelet-derived growth factor receptor, alpha polypeptide

PDGFRA, platelet-derived growth factor receptor, PDGFRalpha
This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies in knockout mice, where homozygosity is lethal, indicate that the alpha form of the platelet-derived growth factor receptor is particularly important for kidney development since mice heterozygous for the receptor exhibit defective kidney phenotypes. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: PDGFR, CAN, HAD, EGFR, Akt
Papers on PDGFRA
High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing.
New
Sepulveda et al., New York City, United States. In Mod Pathol, Feb 2016
Overall, 13 genes had significantly increased CpG methylation in gastric cancer vs non-metaplastic mucosa (BRINP1, CDH11, CHFR, EPHA5, EPHA7, FGF2, FLI1, GALR1, HS3ST2, PDGFRA, SEZ6L, SGCE, and SNRPN).
Bone Morphogenic Protein 4-Smad-Induced Upregulation of Platelet-Derived Growth Factor AA Impairs Endothelial Function.
New
Huang et al., Hong Kong, Hong Kong. In Arterioscler Thromb Vasc Biol, Feb 2016
The effect of PDGF-AA on endothelial function in mouse aorta was also inhibited by Ad-Pdgfra-shRNA to inhibit PDGFRα.
Insulator dysfunction and oncogene activation in IDH mutant gliomas.
New
Impact
Bernstein et al., Boston, United States. In Nature, Feb 2016
We specifically demonstrate that loss of CTCF at a domain boundary permits a constitutive enhancer to interact aberrantly with the receptor tyrosine kinase gene PDGFRA, a prominent glioma oncogene.
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
New
Impact
AGO Study Group led Gynecologic Cancer Intergroup (GCIG)/European Network of Gynaecologic Oncology Trials Groups (ENGOT) Intergroup Consortium et al., Essen, Germany. In Lancet Oncol, Jan 2016
Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting.
Lenvatinib: Role in thyroid cancer and other solid tumors.
Review
New
Habra et al., Houston, United States. In Cancer Treat Rev, Jan 2016
Lenvatinib targets vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR-1-4), RET, c-kit, and platelet-derived growth factor receptor α (PDGFRα).
Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations.
New
Kozacioğlu et al., İzmir, Turkey. In Rare Tumors, Jan 2016
A molecular genetic analysis for KIT (exons 9, 11, 13 and 17) and PDGFRA (exons 12 and 18) genes was performed, in paraffin micro dissection specimens, by the PCR-direct sequencing method.
Immunohistochemical Analysis of PDGFR-α, PDGFR-β and c-Abl in Retinoblastoma: Potential Therapeutic Targets.
New
Burnier et al., Montréal, Canada. In Ophthalmic Res, Dec 2015
AIMS: The purpose of this project was to determine the immunoexpression of platelet-derived growth factor receptor (PDGFR)-α, PDGFR-β and c-Abl in 61 human samples of Rb to determine if IM-sensitive receptors are present.
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
New
Heinrich et al., Berlin, Germany. In Bmc Cancer, Dec 2015
BACKGROUND: Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST) patients.
Endometrial stem/progenitor cells: the first 10 years.
Review
New
Deane et al., Australia. In Hum Reprod Update, Dec 2015
Specific markers for their enrichment have been identified, CD146(+)PDGFRβ(+) (platelet-derived growth factor receptor beta) and SUSD2(+) (sushi domain containing-2), which detected their perivascular location and likely pericyte identity in endometrial basalis and functionalis vessels.
Identification of an oncogenic RAB protein.
New
Impact
Sawyers et al., New York City, United States. In Science, Nov 2015
Furthermore, oncogenic RAB35 is sufficient to drive platelet-derived growth factor receptor α to LAMP2-positive endomembranes in the absence of ligand, suggesting that there may be latent oncogenic potential in dysregulated endomembrane trafficking.
The genomic landscape of response to EGFR blockade in colorectal cancer.
New
Impact
Velculescu et al., Torino, Italy. In Nature, Nov 2015
In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy.
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
New
Impact
Sherman et al., Aş Şanamayn, Syria. In N Engl J Med, Mar 2015
BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).
MicroRNAs and Gastrointestinal Stromal Tumor.
Review
Lui et al., Stockholm, Sweden. In Adv Exp Med Biol, 2014
This tumor type is driven by gain-of-function mutations in receptor tyrosine kinases (such as KIT, PDGFRA, and BRAF) or loss-of-function mutations in succinate dehydrogenase complex subunit genes (SDHx).
Overview of fundamental study of pazopanib in cancer.
Review
Zhou et al., Tianjin, China. In Thorac Cancer, 2014
Through the exploration of inhibitors of vascular endothelial growth factor receptor (VEGFR)-2, deemed as the major angiogenesis pathway, pazopanib was found as a small molecular pan-VEGFR and pan-platelet-derived growth factor receptor (PDGFR) inhibitor, with suitable pharmacodynamic and pharmacokinetic parameters to be an oral drug.
State of the Art in the Treatment of Gastrointestinal Stromal Tumors.
Review
Bruns et al., Magdeburg, Germany. In Gastrointest Tumors, 2014
Despite their biological and clinical heterogeneity, the majority of these tumors are positive for the receptor tyrosine kinase KIT and are driven by KIT- or platelet-derived growth factor receptor alpha (PDGFRA)-activating mutations.
Phf14, a novel regulator of mesenchyme growth via platelet-derived growth factor (PDGF) receptor-α.
GeneRIF
Era et al., Kumamoto, Japan. In J Biol Chem, 2012
Phf14 acts as a negative regulator of PDGFRalpha expression in mesenchymal cells undergoing normal and abnormal proliferation, and is a potential target for new treatments of lung fibrosis.
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.
GeneRIF
Rich et al., Cleveland, United States. In Genes Dev, 2012
Study found that PDGFRalpha is expressed only in a subset of proneural glioblastoma , while PDGFRbeta is more commonly expressed in tumors but is preferentially expressed by self-renewing tumorigenic GBM stem cells.
A KIT-negative, DOG1-positive epithelioid GIST of the stomach harboring a novel PDGFRA exon 14 single nucleotide deletion.
GeneRIF
Mariuzzi et al., Trieste, Italy. In Anticancer Res, 2012
describe a gastric GIST harboring a novel PDGFRA exon 14 frameshift mutation caused by a single-nucleotide deletion
Primary small cell carcinoma of the maxillary sinus: a case report with immunohistochemical and molecular genetic study involving KIT and PDGFRA.
GeneRIF
Terada, Shizuoka, Japan. In Int J Clin Exp Pathol, 2011
Case Report: primary small cell carcinoma of maxillary sinus immunohistochemically positive for KIT/PDGFRA with no mutations of either detected.
An immunohistochemical and molecular genetic analysis of KIT and PDGFRA in small cell lung carcinoma in Japanese.
GeneRIF
Terada, Shizuoka, Japan. In Int J Clin Exp Pathol, 2011
PDGFRA mutations were absent in small cell lung carcinoma and protein expression did not provide prognostic information.
share on facebooktweetadd +1mail to friends